Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Search the Video Library
Filter by Cancer Type:
Displaying Results 1 - 7 of 7
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).
For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer.In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org